ArticleDiabetology & metabolic syndrome2020

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.

Ken Ohara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.